Tandem Diabetes Care (TNDM) Return on Invested Capital (2024 - 2025)
Tandem Diabetes Care (TNDM) posted Return on Invested Capital of 0.03% for Q4 2025, down 63.79% on a QoQ basis from 0.02% in Q3 2025, and down 2.0% year-over-year from 0.03% in Q4 2024.
Tandem Diabetes Care (TNDM) Return on Invested Capital (2024 - 2025) Analysis & Trends
Tandem Diabetes Care's Return on Invested Capital history runs 2 years deep, the most recent figure standing at 0.03% for Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.39 Bn | 174.10 Bn | 6.27 Bn | 0.01% |
| 2 | Stryker | 128.38 Bn | 125.50 Bn | 3.81 Bn | 0.01% |
| 3 | Medtronic | 107.68 Bn | 98.46 Bn | 6.41 Bn | 0.01% |
| 4 | Boston Scientific | 67.98 Bn | 66.53 Bn | 3.61 Bn | 0.00% |
| 5 | Edwards Lifesciences | 47.81 Bn | 44.13 Bn | 1.29 Bn | - |
| 6 | GE HealthCare Technologies | 28.53 Bn | 26.25 Bn | 1.98 Bn | 0.00% |
| 7 | Dexcom | 28.35 Bn | 27.24 Bn | 750.30 Mn | - |
| 8 | Smith & Nephew | 26.78 Bn | 26.20 Bn | - | - |
| 9 | Koninklijke Philips | 25.34 Bn | 22.21 Bn | 2.07 Bn | 0.00% |
| 10 | Tandem Diabetes Care | 1.16 Bn | 585.31 Mn | 136.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.03% |
| Sep 30, 2025 | -0.02% |
| Jun 30, 2025 | -0.01% |
| Mar 31, 2025 | -0.01% |
| Dec 31, 2024 | -0.01% |
| Sep 30, 2024 | -0.02% |